Program
lenvatinib
Also written as “Lenvatinib”, “E7080” and “HOPE”.
Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.
Drug pageLenvatinib: every studyAll 431 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 511 open or running | phase 4since Jun 19, 2018 | Jul 15, 2005 | none ahead |
| Merckits history only | 261 open or running | phase 3since Jan 22, 2019 | Aug 3, 2016 | Oct 22, 2027phase 2 · NCT02861573 |
| AGO Researchits history only | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Oct 4, 2021 | Oct 4, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, PharmaBio Development and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eisai only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Jul 15, 2005.
- Jun 21, 2016Phase 3 study in Carcinoma, Renal CellNCT02811861 · 1,069 enrolled · United States, Australia, Austria and more
- Sep 23, 2016Phase 2 study in Neoplasm MetastasisNCT02915783 · 41 enrolled · United States
- Nov 1, 2016Phase 1 study in Unresectable Hepatocellular Carcinoma (HCC)NCT02953743 · 25 enrolled · China
- Nov 15, 2016Phase 3 study in Differentiated Thyroid Cancer (DTC)NCT02966093 · 151 enrolled · China
- Dec 27, 20163 phase 1 studiesNCT03006926, NCT03006887, NCT03009292
- May 22, 2017Phase 2 study in Carcinoma, Renal CellNCT03173560 · 343 enrolled · United States, Australia, Canada and more
- Aug 3, 2017Phase 2 study in RecurrenceNCT03245151 · 64 enrolled · United States, Canada
- Jan 26, 2018Phase 1 study in Carcinoma, HepatocellularNCT03418922 · 30 enrolled · Japan
- Feb 9, 2018Phase 2 study in Carcinoma, HepatocellularNCT03433703 · 8 enrolled · United States
- Mar 20, 2018Phase 2 study in Solid TumorsNCT03477175 · 40 enrolled · United States, Australia, Belgium and more
- Apr 25, 2018Phase 3 study in Endometrial NeoplasmsNCT03517449 · 827 enrolled · United States, Argentina, Australia and more
- Jun 19, 2018Phase 4 study in Thyroid NeoplasmsNCT03573960 · 50 enrolled · India
- Nov 1, 2019Phase 2 study in OsteosarcomaNCT04154189 · 81 enrolled · United States, Australia, Austria and more
- Mar 4, 2020Phase 4 study in Carcinoma, HepatocellularNCT04297254 · 50 enrolled · India
TargetBeta
“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
All 51 Eisai leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04297254Carcinoma, Hepatocellular · India | 4 | Completed | Jul 31, 2023 | 50 |
| NCT04154189Osteosarcoma · United States, Australia, Austria and more | 2 | Completed | Jun 22, 2022 | 81 |
| NCT03573960Thyroid Neoplasms · India | 4 | Completed | Sep 4, 2025 | 50 |
| NCT03517449Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Mar 1, 2022 | 827 |
| NCT03477175Solid Tumors · United States, Australia, Belgium and more | 2 | Completed | Dec 21, 2023 | 40 |
| NCT03433703Carcinoma, Hepatocellular · United States | 2 | Terminated | Jan 7, 2019 | 8 |
| NCT03418922Carcinoma, Hepatocellular · Japan | 1 | Completed | Dec 28, 2022 | 30 |
| NCT03245151Recurrence · United States, Canada | 2 | Completed | Sep 30, 2022 | 64 |
| NCT03173560Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Feb 14, 2020 | 343 |
| NCT03009292Solid Tumor · China | 1 | Completed | Dec 24, 2018 | 12 |
| NCT03006926Carcinoma, Hepatocellular · United States, France, Italy and more | 1 | Completed | Oct 31, 2019 | 104 |
| NCT03006887Carcinoma, Non-Small-Cell Lung · Japan | 1 | Completed | Apr 15, 2020 | 6 |
| NCT02966093Differentiated Thyroid Cancer (DTC) · China | 3 | Completed | Jul 31, 2019 | 151 |
| NCT02953743Unresectable Hepatocellular Carcinoma (HCC) · China | 1 | Completed | Jun 28, 2017 | 25 |
| NCT02915783Neoplasm Metastasis · United States | 2 | Completed | Nov 2, 2021 | 41 |
| NCT02811861Carcinoma, Renal Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 28, 2020 | 1,069 |
| NCT02702388Thyroid Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Dec 12, 2019 | 241 |
| NCT02686164Neoplasms · United States | 1 | Completed | Jan 4, 2017 | 51 |
| NCT02657369Thyroid Carcinoma, Anaplastic · United States, Australia, France and more | 2 | Terminated | Sep 26, 2018 | 34 |
| NCT02579616Biliary Tract Neoplasms · Japan | 2 | Completed | Nov 22, 2016 | 29 |
| NCT02792829Healthy Volunteers · United States | 1 | Completed | Aug 2014 | 60 |
| NCT02723630Healthy Volunteers · United States | 1 | Completed | Aug 2013 | 60 |
| NCT02578316Lymphoma · Netherlands | 1 | Completed | Jun 2010 | 6 |
| NCT02501096Neoplasms · United States, Norway, Spain | 2 | Completed | Aug 18, 2020 | 357 |
| NCT02454478Carcinoma, Renal Cell · Japan | 1 | Completed | May 29, 2017 | 7 |
| NCT02432274Neoplasms · United States, France, Germany and more | 2 | Completed | Jul 18, 2019 | 117 |
| NCT02421042Hepatic Impairment · United States | 1 | Completed | Jul 2012 | 14 |
| NCT02199392P-glycoprotein · United States | 1 | Completed | Jan 2012 | 15 |
| NCT02199379Renal Insufficiency · United States | 1 | Completed | Oct 2012 | 26 |
| NCT02198170Healthy Volunteers · United States | 1 | Completed | Jun 2011 | 18 |
| NCT01877083Lung Neoplasms · United States, Hong Kong, Japan and more | 2 | Completed | Feb 3, 2016 | 25 |
| NCT01761266Carcinoma, Hepatocellular · United States, Australia, Belgium and more | 3 | Completed | Nov 13, 2016 | 954 |
| NCT01728623Thyroid Neoplasms · Japan | 2 | Completed | Jul 9, 2015 | 51 |
| NCT01525394Lymphoma · United States | 1 | Completed | Aug 2011 | 52 |
| NCT01529112Carcinoma, Non-Small-Cell Lung · United States, Belgium, Czechia and more | 2 | Completed | Jan 21, 2014 | 135 |
| NCT01433991Advanced Solid Tumors · United States | 2 | Terminated | Mar 18, 2015 | 30 |
| NCT01321554Thyroid Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Nov 15, 2013 | 392 |
| NCT01268293Neoplasms · Japan | 1 | Completed | Dec 2011 | 9 |
| NCT01240408Neoplasms · United States | 1 | Completed | Nov 2011 | 16 |
| NCT01137604Glioma · United States, Canada | 2 | Completed | Mar 19, 2013 | 151 |
| NCT01136967Melanoma · United States, Australia, Germany and more | 2 | Completed | Apr 2013 | 182 |
| NCT01136733Carcinoma, Renal Cell · United States, Czechia, Poland and more | 2 | Completed | Jun 13, 2014 | 173 |
| NCT01133977Melanoma · United States, Germany, Italy and more | 2 | Completed | Jun 2014 | 97 |
| NCT01133756Ovarian Neoplasms · United States | 2 | Terminated | Feb 2012 | 7 |
| NCT01111461Endometrial Neoplasms · United States, Belgium, Bulgaria and more | 2 | Completed | May 2012 | 133 |
| NCT00946153Carcinoma, Hepatocellular · Japan, Korea, Republic of | 2 | Completed | Jun 15, 2014 | 66 |
| NCT00832819Carcinoma, Non-Small-Cell Lung · Japan | 1 | Completed | Jul 2011 | 28 |
| NCT00784303Thyroid Neoplasms · United States, Australia, France and more | 2 | Completed | Apr 11, 2011 | 117 |
| NCT00280397Neoplasms · Japan | 1 | Completed | Sep 2008 | 27 |
| NCT00121719Lymphoma · Netherlands, United Kingdom | 1 | Completed | Jun 19, 2009 | 82 |
| NCT00121680Melanoma · United States | 1 | Completed | Sep 2011 | 115 |
How it is read
Names in the registry
- “Lenvatinib”, 72 entries
- “lenvatinib”, 7 entries
- “E7080”, 6 entries
- “HOPE”, 2 entries
- “E7080 capsule”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 10 studies
- Melanoma, 7 studies
- Thyroid Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Renal Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.